Praxis precision medicines provides regulatory update on prax-114 program

Cambridge, mass., nov. 09, 2020 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received a response from the u.s. food and drug administration (fda) on the investigational new drug (ind) submission for prax-114 for the treatment of major depressive disorder (mdd).
PRAX Ratings Summary
PRAX Quant Ranking